Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03727009 · ClinicalTrials.gov registry record
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
A clinical trial, sponsored by Exact Sciences Corporation.
- Terminated
- Registry status
- 409
- Enrollment target
NCT03727009: Clinical Trial study, sponsored by Exact Sciences Corporation.
NCT03727009 is a clinical trial that was terminated before completion, run by Exact Sciences Corporation. The registered enrollment target is 409 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03727009 was terminated before completion, sponsored by Exact Sciences Corporation.
- TERMINATED
- Registry status
- 409 participants
- Enrollment target
Study Summary
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
Primary Outcome
Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood from subjects with a hematologic malignancy at the pre-intervention stage.
Interventions
- OTHER Blood Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2020-03-24 |
Why NCT03727009 stopped before completion
NCT03727009 is an observational study that tracks outcomes without assigning an intervention. The registered 409 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample Collection is the first listed.
NCT03727009 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03727009 about?
NCT03727009 is a clinical study titled "Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies". The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
What is the current status of trial NCT03727009?
This trial is currently terminated. The enrollment target is 409 participants. The study started on 2018-12-07. Estimated completion is 2020-03-24.
What interventions are being tested in trial NCT03727009?
The interventions under investigation include: Blood Sample Collection (OTHER).
Who is sponsoring clinical trial NCT03727009?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717334 · 409 participants
A Study of Lung Cancer Screening in People With Unexplained Weight Loss
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI